Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 14/20 | 1.00 |
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4080806 | 0.90 | CNR1 (0.81) | CNR1CNR2 | |
| SCHEMBL4075789 | 0.89 | CNR1 (0.79) | CNR1CNR2 | |
| SCHEMBL4078116 | 0.88 | CNR1 (0.79) | CNR1CNR2ALDH1A1 | |
| SCHEMBL4089756 | 0.87 | CNR1 (0.77) | CNR1CNR2 | |
| SCHEMBL4085407 | 0.80 | CNR1 (0.66) | CNR1KDM4E | |
| SCHEMBL4075955 | 0.79 | CNR1 (0.66) | CNR1CNR2 | |
| SCHEMBL4085484 | 0.76 | CNR1 (1.00) | CNR1 | |
| SCHEMBL4085731 | 0.75 | CNR1 (0.60) | CNR1 | |
| SCHEMBL4085388 | 0.75 | CNR1 (0.67) | CNR1 | |
| SCHEMBL5355542 | 0.75 | CNR1 (0.59) | CNR1CNR2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7057051-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2006-06-06 | — | — | US | claimed |
| US-20060089356-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2006-04-27 | — | — | US | claimed |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2003-06-19 | — | — | US | claimed |
| WO-2003007887-A2 | SUBSTITUTED IMIDAZOLES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-01-30 | — | — | WO | claimed |
| US-7572785-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572785-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572785-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7057051-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20060089356-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2006-04-27 | — | — | US | disclosed |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089356-A1 | Substituted imidazoles as cannabinoid receptor modulators | CNR1, CNR2, GPR119 | CNR1 1/4885CNR2 2/4885KDM4E 1781/4885 |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | CNR1, CNR2, GPR119 | CNR1 1/4885CNR2 2/4885KDM4E 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.